Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Abeona Therapeutics (ABEO) over the last 9 years, with Sep 2025 value amounting to $22.6 million.

  • Abeona Therapeutics' Other Non-Current Liabilities rose 1951.45% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 1951.45%. This contributed to the annual value of $32.0 million for FY2024, which is 2.11% up from last year.
  • Abeona Therapeutics' Other Non-Current Liabilities amounted to $22.6 million in Q3 2025, which was down 25.17% from $30.2 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Other Non-Current Liabilities ranged from a high of $48.7 million in Q1 2024 and a low of $200,000 during Q1 2022.
  • For the 3-year period, Abeona Therapeutics' Other Non-Current Liabilities averaged around $25.9 million, with its median value being $26.0 million (2023).
  • Per our database at Business Quant, Abeona Therapeutics' Other Non-Current Liabilities soared by 13,461.00% in 2023 and then slumped by 95.94% in 2024.
  • Abeona Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $9.0 million in 2021, then surged by 118.24% to $19.7 million in 2022, then soared by 59.50% to $31.4 million in 2023, then increased by 2.11% to $32.0 million in 2024, then spiked by 1,951.45% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $30.2 million for Q2 2025, and $24.8 million during Q1 2025.